1. Lead Researcher: Jennifer Soung, M.D.

2. Study Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2

3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research study is to find out more about brodalumab in people with moderate to severe plaque psoriasis

4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Adults who have been diagnosed with psoriasis and who are not taking certain prohibited medications

5. Location (if other than UCIMC):
Dermatology Clinical Research Center, University of California, Irvine, 1001 Hewitt Hall, Irvine CA 92697

6. Time Commitment (e.g., three one-hour long visits in three weeks): This study includes 48 visits and takes about 50 hours over a period of approximately 5 years. There will be 25 visits in the first year, 10 visits in the second year and then about 4 visits per year thereafter. You will take study drug (brodalumab, ustekinumab, or placebo) for approximately 5 years, which is the duration of the study.

7. Anticipated Benefits (if any): Taking part in this study may or may not make your health better. While researchers hope that brodalumab will be better than the standard (usual) treatment, there is no proof of this yet. If you are in the group that receives brodalumab and it proves to treat your condition more effectively or with less side effects than the standard treatment, you may benefit from participating in the study, but this cannot be guaranteed

8. Compensation (if any): $35/visit
9. Contact Name, UCI Department, Phone Number and E-mail:
Brian Swasdibutra
UCI Department of Dermatology
949-824-7103
bswasdib@uci.edu

Signature of Lead Researcher: ____________________________ Date: ___________

IRB Approval Granted on: